The new cancer center paradigm provides genetic tests not just for experimental research, but as a clinical standard. In this glimpse by Bloomberg, Memorial Sloan Kettering Cancer Center shows off a new laboratory opened just weeks ago where patients' biopsies will be tested for 341 mutations associated with disease.

“It’s going to fast-forward progress,” Kenneth Anderson, director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber reportedly said. “We can select patient populations for more selective therapy, fewer side effects and faster drug development.”

Sloan Kettering is also collaborating with Quest Diagnostics in order to broaden the spectrum of tested genes to 341 by the end of 2015.